Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
An update from Grifols ( (ES:GRF) ) is now available.
Grifols reported a strong financial performance in the first quarter of 2025, exceeding forecasts with a 7.4% increase in revenues and a 14.2% rise in adjusted EBITDA. The company’s strategic execution and robust demand in the Biopharma sector contributed to a 179% growth in net profit and improved free cash flow by 209 million euros. Despite a temporary dip in albumin sales due to license renewal in China, Grifols maintained a solid liquidity position and reduced its leverage ratio, positioning itself for sustained growth in 2025.
The most recent analyst rating on (ES:GRF) stock is a Buy with a EUR22.00 price target. To see the full list of analyst forecasts on Grifols stock, see the ES:GRF Stock Forecast page.
More about Grifols
Grifols is a global leader in the healthcare sector, specializing in plasma-derived medicines. The company focuses on biopharmaceuticals and diagnostics, with a significant presence in immunoglobulin and other specialty proteins. Grifols operates with a strong local presence in its main markets, maintaining self-sufficient and vertically integrated regional plasma ecosystems.
YTD Price Performance: -11.13%
Average Trading Volume: 2,560,265
Technical Sentiment Signal: Sell
Current Market Cap: €5.06B
See more data about GRF stock on TipRanks’ Stock Analysis page.